What's new — Chronic kidney disease¶
Generated 2026-09-03 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 1 |
| last 2 months | 5 |
| last 3 months | 10 |
| last 6 months | 18 |
| last year | 32 |
| older than a year | 278 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-08-07 | Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis — Lancet Diabetes Endocrinol ([PMID 42567173](https://pubmed.ncbi.nlm.nih.gov/42567173/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glp1-and-emerging-therapy |
| 2026-08-02 | Liberal fruit and vegetable intake in patients with advanced CKD with or without Sodium zirconium cyclosilicate — J Ren Nutr ([PMID 42636918](https://pubmed.ncbi.nlm.nih.gov/42636918/){target="_blank" rel="noopener"}) | diet-and-nutrition |
| 2026-08-01 | Apolipoprotein L1 Gene Genotype and Kidney Outcomes After Living Kidney Donation — JAMA Intern Med ([PMID 42329639](https://pubmed.ncbi.nlm.nih.gov/42329639/){target="_blank" rel="noopener"}) | race-and-the-egfr-equation |
| 2026-07-31 | KDIGO 2026 Clinical Practice Guideline for Anemia in Chronic Kidney Disease (CKD): a commentary from the European Renal Best Practice (ERBP) — Nephrol Dial Transplant ([PMID 41604211](https://pubmed.ncbi.nlm.nih.gov/41604211/){target="_blank" rel="noopener"}) | anaemia-of-ckd |
| 2026-07-21 | Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial — JAMA ([PMID 42246414](https://pubmed.ncbi.nlm.nih.gov/42246414/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — J Am Coll Cardiol ([PMID 42265997](https://pubmed.ncbi.nlm.nih.gov/42265997/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-09 | 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines — Circulation ([PMID 42263157](https://pubmed.ncbi.nlm.nih.gov/42263157/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-05 | Efficacy and safety of finerenone in patients with chronic kidney disease: an individual participant data pooled analysis (INFINITY) — Lancet ([PMID 42248158](https://pubmed.ncbi.nlm.nih.gov/42248158/){target="_blank" rel="noopener"}) | guidelines, mineralocorticoid-receptor-antagonists |
| 2026-06-04 | Finerenone in Persons with Chronic Kidney Disease without Diabetes — N Engl J Med ([PMID 42246672](https://pubmed.ncbi.nlm.nih.gov/42246672/){target="_blank" rel="noopener"}) | clinical-trials-landscape, diabetic-kidney-disease, guidelines, mineralocorticoid-receptor-antagonists |
| 2026-06-04 | Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial — Lancet ([PMID 42242268](https://pubmed.ncbi.nlm.nih.gov/42242268/){target="_blank" rel="noopener"}) | clinical-trials-landscape, glp1-and-emerging-therapy, inherited-and-glomerular-disease |
| 2026-06-01 | Can sodium-glucose cotransporter 2 (SGLT2) inhibition preserve renal structure and function in de novo kidney transplant recipients? Protocol for a randomised, double-blind, placebo-controlled trial assessing the efficacy of dapagliflozin on kidney structure, function and safety in kidney transplant recipients in Norway-the DEAK study — BMJ Open ([PMID 42315275](https://pubmed.ncbi.nlm.nih.gov/42315275/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2026-05-08 | The Effect of Adding Dapagliflozin on Chronic Renal Allograft Dysfunction: A Randomized, Prospective, Double-blind, Placebo-controlled Trial — Transplantation ([PMID 42102257](https://pubmed.ncbi.nlm.nih.gov/42102257/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2026-05-05 | Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals — Nat Med ([PMID 42086979](https://pubmed.ncbi.nlm.nih.gov/42086979/){target="_blank" rel="noopener"}) | guidelines, risk-prediction-and-prognosis |
| 2026-05-01 | A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial — Lancet Diabetes Endocrinol ([PMID 42114520](https://pubmed.ncbi.nlm.nih.gov/42114520/){target="_blank" rel="noopener"}) | glp1-and-emerging-therapy |
| 2026-04-25 | Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis — Lancet ([PMID 42035778](https://pubmed.ncbi.nlm.nih.gov/42035778/){target="_blank" rel="noopener"}) | ras-blockade-and-blood-pressure |
| 2026-04-08 | Endothelin Receptor Antagonist Ambrisentan, Sodium-Glucose Cotransporter 2 Inhibitor Henagliflozin, and Their Combination in IgA Nephropathy: A Randomized Crossover Trial — J Am Soc Nephrol ([PMID 41949916](https://pubmed.ncbi.nlm.nih.gov/41949916/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-04-02 | Clinical and histologic predictors of non-diabetic kidney disease in patients with diabetes mellitus — Kidney Int ([PMID 42034202](https://pubmed.ncbi.nlm.nih.gov/42034202/){target="_blank" rel="noopener"}) | diabetic-kidney-disease |
| 2026-03-05 | Finerenone in Type 1 Diabetes and Chronic Kidney Disease — N Engl J Med ([PMID 41780000](https://pubmed.ncbi.nlm.nih.gov/41780000/){target="_blank" rel="noopener"}) | clinical-trials-landscape, diabetic-kidney-disease, guidelines, mineralocorticoid-receptor-antagonists |
| 2026-03-02 | Iptacopan in IgA Nephropathy - Final 24-Month Data — N Engl J Med ([PMID 41910396](https://pubmed.ncbi.nlm.nih.gov/41910396/){target="_blank" rel="noopener"}) | clinical-trials-landscape, inherited-and-glomerular-disease |
| 2026-01-20 | Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria: A Meta-Analysis — JAMA ([PMID 41202026](https://pubmed.ncbi.nlm.nih.gov/41202026/){target="_blank" rel="noopener"}) | overview, sglt2-inhibitors |
| 2026-01-09 | Chronic Kidney Disease and Superimposed Acute Kidney Injury: Greater Impact of Acute Insults on Outcomes — Int J Nephrol ([PMID 41523706](https://pubmed.ncbi.nlm.nih.gov/41523706/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-01-01 | Executive Summary of the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) — Kidney Int ([PMID 41485807](https://pubmed.ncbi.nlm.nih.gov/41485807/){target="_blank" rel="noopener"}) | anaemia-of-ckd, guidelines |
| 2026-01-01 | Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate Reduction — JAMA Cardiol ([PMID 41369941](https://pubmed.ncbi.nlm.nih.gov/41369941/){target="_blank" rel="noopener"}) | mineralocorticoid-receptor-antagonists |
| 2026-01-01 | 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026 — Diabetes Care ([PMID 41358881](https://pubmed.ncbi.nlm.nih.gov/41358881/){target="_blank" rel="noopener"}) | guidelines |
| 2026-01-01 | Chronic Kidney Disease Prevalence and Awareness Among US Adults — JAMA Cardiol ([PMID 41205219](https://pubmed.ncbi.nlm.nih.gov/41205219/){target="_blank" rel="noopener"}) | causes-and-aetiology, definition-staging-and-measurement, epidemiology-and-burden, guidelines, overview, pathophysiology-and-progression, race-and-the-egfr-equation, risk-prediction-and-prognosis |
| 2025-12-09 | Conservative kidney management versus dialysis for stage 5 chronic kidney disease in older people — Cochrane Database Syst Rev ([PMID 41363177](https://pubmed.ncbi.nlm.nih.gov/41363177/){target="_blank" rel="noopener"}) | conservative-and-supportive-care, kidney-replacement-therapy-decisions, symptom-burden-and-patient-experience |
| 2025-12-02 | Discordance in Creatinine- and Cystatin C-Based eGFR and Clinical Outcomes: A Meta-Analysis — JAMA ([PMID 41202182](https://pubmed.ncbi.nlm.nih.gov/41202182/){target="_blank" rel="noopener"}) | definition-staging-and-measurement |
| 2025-12-01 | Efficacy, Mechanisms, and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial — Clin J Am Soc Nephrol ([PMID 41385300](https://pubmed.ncbi.nlm.nih.gov/41385300/){target="_blank" rel="noopener"}) | clinical-trials-landscape, sglt2-inhibitors |
| 2025-11-07 | Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both: Secondary Analysis of the CONFIDENCE Randomized Trial — J Am Coll Cardiol ([PMID 41493296](https://pubmed.ncbi.nlm.nih.gov/41493296/){target="_blank" rel="noopener"}) | diabetic-kidney-disease, mineralocorticoid-receptor-antagonists, potassium-acidosis-and-metabolic |
| 2025-11-07 | Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023 — Lancet ([PMID 41213283](https://pubmed.ncbi.nlm.nih.gov/41213283/){target="_blank" rel="noopener"}) | epidemiology-and-burden, overview |
| 2025-11-06 | A meta-analysis of albuminuria as a surrogate endpoint for kidney failure — Nat Med ([PMID 41198855](https://pubmed.ncbi.nlm.nih.gov/41198855/){target="_blank" rel="noopener"}) | definition-staging-and-measurement, inherited-and-glomerular-disease, overview |
| 2025-10-01 | Effects of Intensive Systolic Blood Pressure Control on Kidney Outcomes in Patients With and Without CKD: A Post Hoc Analysis of SPRINT and ACCORD-BP Trials — J Diabetes ([PMID 41117098](https://pubmed.ncbi.nlm.nih.gov/41117098/){target="_blank" rel="noopener"}) | ras-blockade-and-blood-pressure |
Trials — what has moved¶
42 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 4 |
| trial records updated in the last month | 11 |
| trial records updated in the last 2 months | 15 |
| trial records updated in the last 3 months | 16 |
| trial records updated in the last 6 months | 22 |
| trial records updated in the last year | 28 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-07-13 | A Study to Learn How Well the Treatment Combination of Finerenone and | PHASE2 | 1664 | Least Squares Mean Ratio of Urinary Albumin-to-Creatinine Ratio (UACR) | 52 | 406 | 6 |
| 2026-01-14 | A Research Study to Find Out How Semaglutide Works in the Kidneys Comp | PHASE3 | 106 | Change in Kidney Oxygenation (Cortex), Blood Oxygenation-level Depende | 19 | 26 | 3 |
| 2025-03-20 | A Research Study to See How Semaglutide Works Compared to Placebo in P | PHASE3 | 3533 | Number of Participants From Time of Randomization to First Occurrence | 1827 | 1029 | 506 |
| 2024-12-03 | Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglo | PHASE3 | 365 | Part A: Ratio of Urine Protein to Creatinine Ratio (UPCR) at 9 Months | 27 | 177 | 1 |
| 2024-07-03 | A Study of the Effect and Safety of Sparsentan in the Treatment of Pat | PHASE3 | 406 | Percent Change From Baseline in the Urine Protein/Creatinine (UP/C) at | 146 | 364 | 1 |
| 2023-07-27 | EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empaglifloz | PHASE3 | 6609 | Interventional Part: Time to First Occurrence of Kidney Disease Progre | 2256 | 490 | 667 |
| 2022-04-15 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mel | PHASE3 | 7352 | The First Occurrence of the Composite Endpoint of Cardiovascular Death | 2373 | 3514 | 722 |
| 2021-07-19 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mel | PHASE3 | 5734 | The First Occurrence of the Composite Endpoint of Onset of Kidney Fail | 1873 | 3186 | 472 |
| 2021-07-07 | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and | PHASE3 | 4304 | Time to the First Occurrence of Any of the Components of the Composite | 1362 | 979 | 266 |
| 2019-11-20 | Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular | PHASE3 | 4401 | Primary Composite Endpoint of Doubling of Serum Creatinine (DoSC), End | 1543 | 2767 | 357 |
29 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.